COSCIENS Biopharma Inc. (CSCI)
NASDAQ: CSCI · Real-Time Price · USD
3.200
+0.050 (1.59%)
Apr 25, 2025, 4:00 PM EDT - Market closed
COSCIENS Biopharma Revenue
In the year 2024, COSCIENS Biopharma had annual revenue of $9.59M with 34.22% growth. COSCIENS Biopharma had revenue of $3.32M in the quarter ending December 31, 2024, with 20.10% growth.
Revenue (ttm)
$9.59M
Revenue Growth
+34.22%
P/S Ratio
1.05
Revenue / Employee
$239,675
Employees
40
Market Cap
10.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.59M | 2.44M | 34.22% |
| Dec 31, 2023 | 7.14M | -7.43M | -50.98% |
| Dec 31, 2022 | 14.57M | 9.31M | 177.03% |
| Dec 31, 2021 | 5.26M | 1.61M | 44.03% |
| Dec 31, 2020 | 3.65M | 3.12M | 586.47% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
CSCI News
- 16 days ago - COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 24 days ago - COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - GlobeNewsWire
- 5 weeks ago - COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents - Newsfile Corp
- 6 weeks ago - COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product - GlobeNewsWire
- 4 months ago - COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization - GlobeNewsWire
- 5 months ago - COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs - GlobeNewsWire
- 7 months ago - COSCIENS Biopharma Announces Change to Board of Directors - GlobeNewsWire
- 7 months ago - COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director - GlobeNewsWire